250 related articles for article (PubMed ID: 31087564)
1. Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program.
Jacot W; Heudel PE; Fraisse J; Gourgou S; Guiu S; Dalenc F; Pistilli B; Campone M; Levy C; Debled M; Leheurteur M; Chaix M; Lefeuvre C; Goncalves A; Uwer L; Ferrero JM; Eymard JC; Petit T; Mouret-Reynier MA; Courtinard C; Cottu P; Robain M; Mailliez A
Int J Cancer; 2019 Dec; 145(12):3359-3369. PubMed ID: 31087564
[TBL] [Abstract][Full Text] [Related]
2. Systematic review of Real-World effectiveness of eribulin for locally advanced or metastatic breast cancer.
Chabot I; Zhao Q; Su Y
Curr Med Res Opin; 2020 Dec; 36(12):2025-2036. PubMed ID: 33044090
[TBL] [Abstract][Full Text] [Related]
3. A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes.
Kimura K; Iwamoto M; Tanaka S; Yamamoto D; Yoshidome K; Ogura H; Terasawa R; Matsunami N; Takahashi Y; Nitta T; Morimoto T; Fujioka H; Kawaguchi K; Uchiyama K
Cancer Chemother Pharmacol; 2018 May; 81(5):923-933. PubMed ID: 29594360
[TBL] [Abstract][Full Text] [Related]
4. Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study.
Manso L; Moreno Antón F; Izarzugaza Perón Y; Delgado Mingorance JI; Borrega García P; Echarri González MJ; Martínez-Jañez N; López-González A; Olier Garate C; Ballesteros García A; Chacón López-Muñíz I; Ciruelos Gil E; García-Sáenz JA; Paz-Ares L
Breast J; 2019 Mar; 25(2):219-225. PubMed ID: 30734437
[TBL] [Abstract][Full Text] [Related]
5. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.
Ortega V; Antón A; Garau I; Afonso N; Calvo L; Fernández Y; Martínez-García M; Blanco E; Zamora P; García M; Illarramendi JJ; Rodríguez Sánchez CA; Sampayo M; Aguirre E; Pérez-García JM; Cortés J; Llombart-Cussac A
Clin Breast Cancer; 2019 Apr; 19(2):105-112. PubMed ID: 30679100
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.
McIntyre K; O'Shaughnessy J; Schwartzberg L; Glück S; Berrak E; Song JX; Cox D; Vahdat LT
Breast Cancer Res Treat; 2014 Jul; 146(2):321-8. PubMed ID: 24699910
[TBL] [Abstract][Full Text] [Related]
7. Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective Study.
Pedersini R; Vassalli L; Claps M; Tulla A; Rodella F; Grisanti S; Amoroso V; Roca E; Simoncini EL; Berruti A
Oncology; 2018; 94 Suppl 1(Suppl 1):10-15. PubMed ID: 30036867
[TBL] [Abstract][Full Text] [Related]
8. Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens.
Cabel L; Carton M; Cheaib B; Pierga JY; Dalenc F; Mailliez A; Levy C; Jacot W; Debled M; Leheurteur M; Desmoulins I; Lefeuvre C; Gonçalves A; Uwer L; Ferrero JM; Eymard JC; Petit T; Mouret-Reynier MA; Perrocheau G; Piot I; Pérol D; Simon G; Lerebours F
Breast Cancer Res Treat; 2019 Jan; 173(2):397-406. PubMed ID: 30357526
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.
Iizumi S; Shimoi T; Tsushita N; Bun S; Shimomura A; Noguchi E; Kodaira M; Yunokawa M; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
BMC Cancer; 2017 Dec; 17(1):819. PubMed ID: 29202787
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.
Maeda S; Saimura M; Minami S; Kurashita K; Nishimura R; Kai Y; Yano H; Mashino K; Mitsuyama S; Shimokawa M; Tamura K;
Breast; 2017 Apr; 32():66-72. PubMed ID: 28056400
[TBL] [Abstract][Full Text] [Related]
11. Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers - ESEMPiO study.
Barni S; Livraghi L; Morritti M; Vici P; Michelotti A; Cinieri S; Fontanella C; Porcu L; Del Mastro L; Puglisi F;
Future Oncol; 2019 Jan; 15(1):33-44. PubMed ID: 30411979
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting.
Inoue K; Takahashi M; Mukai H; Yamanaka T; Egawa C; Sakata Y; Ikezawa H; Matsuoka T; Tsurutani J
Invest New Drugs; 2020 Oct; 38(5):1540-1549. PubMed ID: 31950374
[TBL] [Abstract][Full Text] [Related]
13. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy.
Pivot X; Marmé F; Koenigsberg R; Guo M; Berrak E; Wolfer A
Ann Oncol; 2016 Aug; 27(8):1525-31. PubMed ID: 27177860
[TBL] [Abstract][Full Text] [Related]
14. Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center.
Sirvén MB; Fernández-Ortega A; Stradella A; Morilla I; Falo C; Vázquez S; Castany R; Villanueva R; Recalde S; Pérez VN; Gil-Gil M; Pernas S
BMC Pharmacol Toxicol; 2019 Nov; 20(1):68. PubMed ID: 31753013
[TBL] [Abstract][Full Text] [Related]
15. Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.
Aftimos P; Polastro L; Ameye L; Jungels C; Vakili J; Paesmans M; van den Eerenbeemt J; Buttice A; Gombos A; de Valeriola D; Gil T; Piccart-Gebhart M; Awada A
Eur J Cancer; 2016 Jun; 60():117-24. PubMed ID: 27107326
[TBL] [Abstract][Full Text] [Related]
16. Use of Eribulin mesylate as second-line therapy in elderly patients with HER/2 negative metastatic breast cancer (MBC): efficacy, tolerability and Quality of Life.
De Luca R; Alù M; Genova G; Grassadonia A; Cicero G
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12727-12734. PubMed ID: 33378020
[TBL] [Abstract][Full Text] [Related]
17. Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study.
Dell'Ova M; De Maio E; Guiu S; Roca L; Dalenc F; Durigova A; Pinguet F; Bekhtari K; Jacot W; Pouderoux S
BMC Cancer; 2015 Oct; 15():659. PubMed ID: 26449988
[TBL] [Abstract][Full Text] [Related]
18. Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial.
Krasniqi E; Pizzuti L; Valerio MR; Capomolla E; Botti C; Sanguineti G; Marchetti P; Anselmi E; Tomao S; Giordano A; Ficorella C; Cannita K; Livi L; Meattini I; Mauri M; Greco F; Veltri EM; Michelotti A; Moscetti L; Giotta F; Lorusso V; Paris I; Tomao F; Santini D; Tonini G; Villa A; Gebbia V; Gamucci T; Ciliberto G; Sperduti I; Mazzotta M; Barba M; Vici P
Int J Med Sci; 2021; 18(10):2245-2250. PubMed ID: 33859534
[No Abstract] [Full Text] [Related]
19. Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national study.
Le Saux O; Lardy-Cleaud A; Frank S; Debled M; Cottu PH; Pistilli B; Vanlemmens L; Leheurteur M; Lévy C; Laborde L; Uwer L; D'hondt V; Berchery D; Lorgis V; Ferrero JM; Perrocheau G; Courtinard C; Mouret-Reynier MA; Velten M; Breton M; Parent D; Chabaud S; Robain M; Bachelot T
Eur J Cancer; 2019 Sep; 118():131-141. PubMed ID: 31330488
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.
Delaloge S; Pérol D; Courtinard C; Brain E; Asselain B; Bachelot T; Debled M; Dieras V; Campone M; Levy C; Jacot W; Lorgis V; Veyret C; Dalenc F; Ferrero JM; Uwer L; Kerbrat P; Goncalves A; Mouret-Reynier MA; Petit T; Jouannaud C; Vanlemmens L; Chenuc G; Guesmia T; Robain M; Cailliot C
Ann Oncol; 2016 Sep; 27(9):1725-32. PubMed ID: 27436849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]